Core Insights - The company is focused on driving profitable growth and enhancing patient care through AI-powered innovations and strategic partnerships, such as the agreement with the Indonesian Ministry of Health to provide nationwide coverage for advanced therapies [2][9]. Group and Segment Performance - Comparable order intake growth improved to 6%, following a 9% growth in Q2 2024, while group comparable sales increased by 1% [4]. - Adjusted EBITA margin rose by 130 basis points to 12.4%, attributed to higher gross margins from innovation and productivity measures, which offset tariff and currency impacts [4]. - Free cash flow increased to EUR 230 million [4]. Segment Analysis - Diagnosis & Treatment comparable sales decreased by 1%, but adjusted EBITA margin improved by 130 basis points to 13.5% due to gross margin improvements [5]. - Connected Care comparable sales also decreased by 1%, with adjusted EBITA margin improving by 160 basis points to 10.4% driven by innovation [5]. - Personal Health comparable sales increased by 6%, with growth across most regions, although there was a decline in China; adjusted EBITA margin declined by 170 basis points to 15.2% due to increased advertising and promotions [6]. Innovation Highlights - The company launched several AI-driven products, including the SmartSpeed Precise MR software, which offers faster scans and sharper images [9]. - New partnerships in the US and Europe aim to enhance monitoring capabilities and patient care through AI technologies [10]. Productivity Initiatives - Cost management and productivity initiatives resulted in savings of EUR 197 million in the quarter, contributing to a three-year productivity program targeting EUR 2.5 billion in savings [11]. Outlook - The company has updated its full-year outlook, increasing expectations for adjusted EBITA margin and free cash flow, while reiterating comparable sales growth outlook of 1%-3% [15]. - The adjusted EBITA margin range has been increased to 11.3%-11.8%, reflecting a 50 basis point increase from previous estimates [15].

Core Insights - The company is focused on driving profitable growth and enhancing patient care through AI-powered innovations and strategic partnerships, such as the agreement with the Indonesian Ministry of Health to provide nationwide coverage for advanced therapies [2][9] - The company reported improved sales and margin expansion, with a notable increase in free cash flow, indicating strong operational performance and effective cost management [3][4][11] Group and Segment Performance - Comparable order intake growth improved to 6%, following a 9% growth in Q2 2024, while group comparable sales increased by 1% [4] - Adjusted EBITA margin rose by 130 basis points to 12.4%, driven by higher gross margins from innovation and productivity measures [4][8] - Free cash flow increased to EUR 230 million, reflecting strong financial health [4][8] Segment Analysis - Diagnosis & Treatment comparable sales decreased by 1%, but adjusted EBITA margin improved by 130 basis points to 13.5% due to gross margin improvements [5] - Connected Care comparable sales also decreased by 1%, with adjusted EBITA margin improving by 160 basis points to 10.4% [5] - Personal Health comparable sales increased by 6%, with growth across most regions, although there was a decline in China; adjusted EBITA margin declined by 170 basis points to 15.2% due to increased advertising and promotions [6] Innovation Highlights - The company launched several AI-powered innovations, including the SmartSpeed Precise MR software, which enhances imaging speed and quality [9] - New product launches include the Flash Ultrasound System 5100 POC and the i9000 electric shaver range, which have received positive market responses [14] Productivity and Cost Management - The company achieved savings of EUR 197 million through disciplined cost management and productivity initiatives, on track to meet a three-year EUR 2.5 billion productivity program [11] Outlook - The company has updated its full-year outlook, increasing expectations for adjusted EBITA margin and free cash flow, while reiterating comparable sales growth outlook of 1%-3% [15]